GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

I attended my high school reunion and had no anxiety about appearance,” Sarah gushed. “My new problem was graciously ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

As 2025 ushers in a new era of weight loss resolutions, many Americans are abandoning traditional gym-first approaches in ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

去年这个时候，人们还在争论诺和诺德（NVO.US）的Wegovy和礼来（LLY.US）的Zepbound是减肥的捷径还是医学上的突破。但是，随着大量数据表明这些药物的健康益处不仅仅是减少肥胖——包括减轻心脏病、糖尿病、慢性肾病和睡眠呼吸暂停——大多数人似乎终于接受了它们潜在的巨大社会价值。

近年来，减肥药物市场一度成为投资者关注的焦点，随着Novo Nordisk的Wegovy和Eli ...

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

两项重磅试验2025年揭晓 ...